技术与方法 |
|
|
|
|
以MERS-CoV主蛋白酶为靶点的药物筛选体系的建立及应用 |
张宁1,3, 潘丽1,3, 牛国君3, 王文明4, 周红刚2, 杨诚2,3 |
1. 天津科技大学生物工程学院 天津 300457; 2. 南开大学药学院 天津 300457; 3. 天津市国际生物医药联合研究院有限公司 天津 300457; 4. 南开大学生命科学学院 天津 300457 |
|
Establishment and Application of a System for Drug Screening Targeting MERS-CoV Main Proteinase |
ZHANG Ning1,3, PAN Li1,3, NIU Guo-jun3, WANG Wen-ming4, ZHOU Hong-gang2, YANG Cheng2,3 |
1. College of Biological Engineering, Tianjin University of Science & Technology, Tianjin 300457, China; 2. College of Pharmacy, Nankai University, Tianjin 300457, China; 3. Tianjin International Joint Academy of Biomedicine Co.Ltd., Tianjin 300457, China; 4. College of Life Sciences, Nankai University, Tianjin 300457, China |
引用本文:
张宁, 潘丽, 牛国君, 王文明, 周红刚, 杨诚. 以MERS-CoV主蛋白酶为靶点的药物筛选体系的建立及应用[J]. 中国生物工程杂志, 2013, 33(12): 51-56.
ZHANG Ning, PAN Li, NIU Guo-jun, WANG Wen-ming, ZHOU Hong-gang, YANG Cheng. Establishment and Application of a System for Drug Screening Targeting MERS-CoV Main Proteinase. China Biotechnology, 2013, 33(12): 51-56.
链接本文:
https://manu60.magtech.com.cn/biotech/CN/
或
https://manu60.magtech.com.cn/biotech/CN/Y2013/V33/I12/51
|
[1] Zaki A M, van Boheemen S, Bestebroer T M, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med, 2012, 367(19):1814-1820. [2] Bermingham A, Chand M A, Brown C S, et al. Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012.Euro Surveill, 2012, 17(40):20290. [3] World Health Organization. Novel coronavirus infection-update. http://www.who.int/csr/disease/coronavirus_infections/update_20130813/en/index.html. [4] Raoul J de Groot, Susan C Baker, Ralph S Baric, et al. Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Announcement of the coronavirus study group. Journal of Virology, 2013, 87(14):7790-7792. [5] van Boheemen S, de Graaf M, Lauber C, et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio, 2012, 3(6): e00473-12. [6] Lu G, Liu D. SARS-like virus in the Middle East: a truly bat-related coronavirus causing human diseases. Protein Cell, 2012, 3(11):803-805. [7] Memish A Ziad, Nischay Mishra, Kevin J, et al. Middle East Respiratory Syndrome Coronavius in Bats, Saudi Arabia. Emerging Infectious Diseases, 2013, (in press). [8] Reusken C B, Haagmans B L, MÜller M A, et al. Middle East respiratory syndrome coronavirus neutralizing serum antibodies in dromedary camels: a comparative serological study. The Lancet Infect Diseases, 2013, (in press). [9] Raj V S, Mou H, Smits S L, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature, 2013, 495(7440):251-254. [10] Lu G, Hu Y, Wang Q, et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature, 2013, 500(7461):227-231. [11] Yang H, Bartlam M, Rao Z. Drug design targeting the main protease, the Achilles heel of coronaviruses. Curr Pharm Des. 2006, 12(35):4573-4590. [12] Ren Z, Yan L, Zhang N, et al. The newly emerged SARS-like coronavirus HCoV-EMC also has an Achilles' heel": current effective inhibitor targeting a 3C-like protease. Protein Cell. 2013, 4(4):248-250. [13] Ziebuhr J, Heusipp G, Siddell S G. Biosynthesis, purification and characterization of the human coronavirus 229E 3C-like proteinase. J Virol, 1997, 71(5):3992-3997. [14] Barnard D L, Kumaki Y. Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy. Future Virol, 2011, 6(5):615-631. [15] Thanigaimalai P, Konno S, Yamamoto T, et al. Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: Design, synthesis, biological evaluation, and docking studies. Eur J Med Chem, 2013, (in press). [16] Zhao Q, Weber E, Yang H. Recent developments on coronavirus main protease/3C like protease inhibitors. Recent Pat Anbiinfect Drug Discovery, 2013, 8(2):150-156. [17] Blanchard J E, Elowe N H, Huitema C, et al. High-throughput screening identifies inhibitors of the SARS coronavirus main proteinase. Chem Biol, 2004, 11(10):1445-1453. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|